Genetic Innovation Offers Solution to PRRS in Pig Farming

The introduction of a gene-editing innovation by PIC promises to alleviate the struggles faced by pig farmers worldwide as they combat Porcine Reproductive and Respiratory Syndrome (PRRS). This disease has caused significant suffering among pigs and economic losses in the pork industry, estimated at $1.2 billion annually in the United States alone from 2016 to 2020.

Matt Culbertson, Chief Operating Officer of PIC, stated, “This isn’t a change to pork; it’s a change to how pigs are protected from a devastating animal disease.” The innovative approach involves removing a specific genetic vulnerability that allows the PRRS virus to infect pigs, enhancing their resilience.

Economic Impact of PRRS

Recent research conducted by Dr. Derald Holtkamp, an associate professor of veterinary diagnostic and production animal medicine at Iowa State University, highlights the escalating impact of PRRS. The disease is increasingly problematic, with the second quarter of 2025 recording the highest number of outbreaks among pigs during critical growth phases since 2013, according to the U.S. Department of Agriculture (USDA).

The development of PRRS-resistant pigs could lead to decreased reliance on antibiotics, improved animal welfare, and a reduced environmental footprint. Culbertson emphasized the nature of this innovation, stating, “Nothing foreign was added and no genes were inserted, meaning this is not a GMO. It’s a healthier pig, bred through a science-driven solution.”

The gene-editing process began over six years ago, allowing for the natural transmission of PRRS resistance through traditional breeding methods.

Consumer Sentiment and Regulatory Approval

To gauge consumer reactions, PIC collaborated with Circana, a leading advisor on consumer behavior. Their findings revealed that pork from PRRS-resistant pigs received above-average purchase likelihood scores. Notably, female consumers indicated a 90% likelihood of purchasing this pork after learning that its taste and safety remain unchanged compared to conventional pork.

Staci Covkin, Principal of Innovation, Consumer and Shopper Insights at Circana, remarked, “Circana concept testing has a 90%+ accuracy rate on consumer behavior predictions.” The results indicated that concepts scoring in the top quintile are often market leaders.

The U.S. Food and Drug Administration (FDA) granted approval for the gene edit used in breeding PRRS-resistant pigs in April 2025. Additionally, countries such as Colombia, Brazil, the Dominican Republic, and Argentina have recognized these pigs as non-GMO and will regulate them similarly to traditional pigs.

Culbertson elaborated on the rigorous process leading to FDA approval, stating, “Earning FDA approval was a years-long process, involving rigorous review of third-party research and multiple generations of pigs.” PRRS-resistant pigs now join a growing list of FDA-approved gene edits in agriculture.

For over 60 years, PIC has focused on enhancing genetics and improving animal efficiency. Through collaboration with academic researchers, the company has successfully developed the PRRS-resistant pig, reinforcing its commitment to innovation in animal agriculture. As a subsidiary of Genus, a UK-based company, PIC operates in more than 40 countries, aiming to pioneer genetic improvements that contribute to sustainable food production.

For further details, visit PRRSResistantPig.com.